Back to Top

Annemieke DeMaggio's blog

Enasidenib fails OS endpoint in confirmatory phase 3 study

The phase 3 IDHENTIFY study failed to show OS benefit with enasidenib compared to standard treatment options in IDH2mut, r/r AML (BMS press release)

Phase III CROWN meets primary endpoint PFS in ALKpos, advanced NSCLC

The confirmatory CROWN study compared lorlatinib to crizotinib in tx-naïve, ALKpos NSCLC. The study met its’ primary endpoint (PFS by BIRC) at interim analysis. Data has not been presented (Pfizer press release).


Subscribe to RSS - Annemieke DeMaggio's blog